A company that funds life-saving innovation in the healthcare sector.

415C

415 Capital is a specialist venture capital firm dedicated to investing in breakthrough and life-saving medical innovation. For over 30 years, our team has empowered exceptional entrepreneurs through the provision of capital, expertise, and market access.

We exclusively invest in large unmet patient needs in chronic diseases, with an emphasis on cardio & neurovascular disorders, the worldwide leading causes of death and the largest cost driver in the global healthcare systems. Our mission is to improve patient outcomes and quality of life at lower long-term healthcare costs.

Over the years, the 415 team has introduced over 25 breakthrough technologies to market and realized over 20 successful portfolio exits to-date, including Vesper Medical and Intact Vascular (both acquired by Philips), Claret Medical (acquired by Boston Scientific), ReCor Medical (acquired by Otsuka), CardiAQ Valve Technologies (acquired by Edwards), Atritech (acquired by Boston Scientific), CoreValve (acquired by Medtronic) and many more.

415 Capital

📢 Are you an organized, detail-oriented individual with exceptional multitasking abilities? Are you passionate about supporting a dynamic team in the fast-paced world of venture capital? If so, we have an exciting opportunity for you!
 
415 Capital is looking for an Executive Assistant (m/f/d) to join its MedTech Venture Capital team in the Munich area.
 
Visit our careers page at https://lnkd.in/dfu7D6jR to view the full job description and submit your application. We look forward to hearing from you!
 
Feel free to share this post or tag someone who might be interested.

415 Capital at the medtech strategist innovation summit in Dublin
#cardioandneurovascular is special

Congratulations to our portfolio company Aktiia for making it onto the Sifted 30 Leaderboard as one of Central Europe's fastest growing start-ups! 

No. 12: Aktiia

cc: Josep Solà Mattia Bertschi Daniel Graf 

🚀🚀🚀

We’re excited to share that Aktiia has achieved regulatory approval (CE mark) for their groundbreaking optical blood pressure (BP) monitor, which does not require calibration with a regular cuff. 👏 

Approval of Aktiia's CALFREE technology will allow it to offer integration of its medical-grade optical blood pressure monitoring to third-party companies developing consumer devices, such as smartwatches, smartphone cameras and smart bands.

We congratulate Aktiia and the entire team for achieving this significant milestone!

cc: Mattia Bertschi, Josep Solà

https://lnkd.in/eMnPs-VC

Congratulations to Ramon L. Varcoe, The Prince of Wales Hospital Sydney, and R3 Vascular Inc. on this great first case in Australia!

Last week, 415 Capital had the privilege of attending the Med-Tech World Summit in Malta.

Our principal, Linus Rieder, shared insights as a panelist, shedding light on the evolving landscape of venture capital in the med-tech industry. Additionally, he had the pleasure of engaging with entrepreneurs as a judge in the startup competition.

A special highlight: we are honored to have been recognized as the "Med-tech VC of the Year".

Thank you to everyone who has been part of our journey, and a big thank you to the organizers of Med-Tech World and Giovanni Lauricella and Lifeblood | Capital + Talent!

#MedTechWorldSummit #mtw2023  #venturecapital  #415Capital #mtw2023  #innovation  #medtech  #technology

Metric
Company Name	415
Symbol
MSH ID	COM:415CAPITAL
Market	PRIVATE
Sector	Financial Services & Finance
Industry	Healthcare investment
Country	DE
Stage
Employee Count	10
Website	415capital.com
LinkedIn	415-capital
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

415C

COM:415CAPITAL

415C

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue